151 related articles for article (PubMed ID: 31192543)
21. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
22. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance.
Feng C; Li Y; Li K; Lyu Y; Zhu W; Jiang H; Wen H
J Exp Clin Cancer Res; 2021 Sep; 40(1):308. PubMed ID: 34593007
[TBL] [Abstract][Full Text] [Related]
23. High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival.
Rabjerg M; Oliván-Viguera A; Hansen LK; Jensen L; Sevelsted-Møller L; Walter S; Jensen BL; Marcussen N; Köhler R
PLoS One; 2015; 10(4):e0122992. PubMed ID: 25848765
[TBL] [Abstract][Full Text] [Related]
24. Prolyl Hydroxylase 3 Knockdown Accelerates
Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686
[TBL] [Abstract][Full Text] [Related]
25. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
26. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
27. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitin-specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF-κB pathway inactivation.
Gui D; Dong Z; Peng W; Jiang W; Huang G; Liu G; Ye Z; Wang Y; Xu Z; Fu J; Luo S; Zhao Y
Cancer Med; 2021 Jun; 10(11):3674-3688. PubMed ID: 33973730
[TBL] [Abstract][Full Text] [Related]
29. Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.
Muscella A; Vetrugno C; Biagioni F; Calabriso N; Calierno MT; Fornai F; De Pascali SA; Marsigliante S; Fanizzi FP
Br J Pharmacol; 2016 Sep; 173(17):2633-44. PubMed ID: 27351124
[TBL] [Abstract][Full Text] [Related]
30. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
31. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma.
Grépin R; Guyot M; Giuliano S; Boncompagni M; Ambrosetti D; Chamorey E; Scoazec JY; Negrier S; Simonnet H; Pagès G
Cancer Res; 2014 Feb; 74(3):873-83. PubMed ID: 24335961
[TBL] [Abstract][Full Text] [Related]
32. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
33. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of vascular endothelial growth factor-D expression in clear cell renal cell carcinoma by CD74: a critical role in cancer cell tumorigenesis.
Liu YH; Lin CY; Lin WC; Tang SW; Lai MK; Lin JY
J Immunol; 2008 Nov; 181(9):6584-94. PubMed ID: 18941249
[TBL] [Abstract][Full Text] [Related]
35. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
[TBL] [Abstract][Full Text] [Related]
37. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
40. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
Wang M; Sun Y; Xu J; Lu J; Wang K; Yang DR; Yang G; Li G; Chang C
Int J Cancer; 2018 Jul; 143(1):100-112. PubMed ID: 29396852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
